Welcome to our dedicated page for Jaguar Health news (Ticker: JAGX), a resource for investors and traders seeking the latest updates and insights on Jaguar Health stock.
Jaguar Health, Inc. develops plant-derived prescription medicines for gastrointestinal disease states in people and animals. Its human-health news centers on crofelemer, including Mytesi for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy and rare-disease intestinal failure programs tied to microvillus inclusion disease and short bowel syndrome through Napo Pharmaceuticals and Napo Therapeutics.
Company updates also cover animal-health products such as conditionally approved Canalevia-CA1 for chemotherapy-induced diarrhea in dogs and the Neonorm franchise for gut health in animals. Recurring corporate news includes Nasdaq listing-compliance matters, reverse stock splits, warrant exercises, stockholder meetings, proxy proposals, and other capital-structure actions.
Jaguar Health, Inc. (NASDAQ:JAGX) has successfully closed the first $6 million tranche of a non-dilutive royalty financing transaction, potentially totaling $17 million, to support ongoing clinical trials for Mytesi (crofelemer). This financing will aid in developing treatments for cancer therapy-related diarrhea. Additionally, Jaguar has amended its agreement with Oasis Capital, allowing for $2,117,875.20 in accounts receivable purchases. The company aims to achieve financial sustainability in 2021 and has seen a 378% increase in Mytesi's Q2 2020 sales compared to Q1.
Jaguar Health, through its subsidiary Napo Pharmaceuticals, has launched a pivotal Phase 3 trial for crofelemer (Mytesi) aimed at preventing diarrhea in adult cancer patients undergoing targeted therapy. This 24-week, randomized, placebo-controlled study aims to address a significant unmet need as diarrhea affects over 650,000 chemotherapy patients in the U.S. annually. The trial is supported by an increased non-dilutive financing deal, now totaling $17 million, anticipated to expedite patient enrollment and site activation. Mytesi is FDA-approved for HIV/AIDS-related diarrhea, showcasing its therapeutic potential.
Jaguar Health (NASDAQ:JAGX) announced that it has met the financial condition for an initial $5 million tranche of a potential $16 million non-dilutive royalty financing transaction. This financing is designed to support its development pipeline, particularly funding a pivotal clinical trial for Mytesi (crofelemer) aimed at treating cancer therapy-related diarrhea. The company has initiated an at-the-market program with Ladenburg Thalmann for future financing needs and anticipates the trial to start in Q4 2020.
Jaguar Health (NASDAQ:JAGX) announced a non-dilutive royalty financing agreement with a secured lender, securing $5 million for future royalties on Mytesi (crofelemer) sales. This funding will support regulatory activities, including a pivotal clinical trial for cancer therapy-related diarrhea (CTD), expected to commence in Q4 2020. The agreement may allow for additional financing up to $16 million by July 2021. CEO Lisa Conte emphasized that this option will not dilute shareholder equity and is based on the growing sales of Mytesi for HIV-related diarrhea.
Jaguar Health (NASDAQ:JAGX) announced that its subsidiary, Napo Pharmaceuticals, is sponsoring the National Trans Visibility March (NTVM) starting September 28, 2020. In conjunction with this event, Napo will host a virtual workshop on the gastrointestinal (GI) consequences of HIV on September 30, 2020, led by advocate Marissa Miller. Jaguar focuses on plant-based, non-opioid medicines for GI distress, with its product Mytesi approved for treating noninfectious diarrhea in HIV/AIDS patients. The company emphasizes its commitment to health equity and support for marginalized communities.
Jaguar Health (NASDAQ:JAGX) will host its inaugural Diarrhea Dialogues virtual event on October 20, 2020, from 3:00 PM to 4:30 PM EDT. The event focuses on supportive care for cancer patients, specifically addressing debilitating diarrhea caused by cancer therapies. Esteemed oncologists, patient advocates, and Jaguar executives will participate, discussing the significant impact of diarrhea on treatment and quality of life. Additionally, Napo Pharmaceuticals, a subsidiary of Jaguar, is advancing research on Mytesi (crofelemer) for the relief of therapy-related diarrhea.
Jaguar Health, Inc. (NASDAQ:JAGX) will present at the 2020 H.C. Wainwright 22nd Annual Global Investment Conference on September 16 at 3:00 PM ET. Founder and CEO Lisa Conte will lead the presentation, which focuses on the company's innovative, plant-based pharmaceuticals for gastrointestinal distress. Institutional investors can register for the conference here to arrange one-on-one meetings with Jaguar.
Jaguar's Mytesi (crofelemer) is FDA-approved for noninfectious diarrhea relief in adults with HIV/AIDS.
Jaguar Health, Inc. (JAGX) announced a third amendment to its accounts receivable purchase agreement with Oasis Capital, LLC, allowing Oasis to purchase an additional $2,329,662.72 in accounts receivable related to the sales of Mytesi drug product. This financing aims to enhance the company's cash flow without diluting shareholder equity.
The agreement entails a purchase price of $990,106.65 and a transaction fee of $5,000. This follows the success of previous tranches and indicates Jaguar's commitment to a stable cash flow positive business strategy.
Jaguar Health, Inc. (JAGX) announced on September 2, 2020, it has completed transactions boosting its stockholders' equity above $5 million, meeting the Nasdaq Capital Market's initial listing requirement. Previously, the company reported $1,544,000 in equity at the end of June 2020. The transactions involved exchanging shares of preferred stock and issuing common stock, completed on September 1, 2020. These efforts aim to address a prior notification from Nasdaq regarding a breach of listing rules due to insufficient equity.
Jaguar Health, Inc. (NASDAQ:JAGX) provided updates on its investigator-initiated trials of crofelemer (Mytesi), a plant-based FDA-approved medication. Trials include: 1) Chronic Idiopathic Diarrhea, with full enrollment expected by 2020 year-end and results by mid-2021; 2) Functional Diarrhea, starting enrollment in Q4 2020 with results also anticipated in Q4 2021; and 3) Diarrhea in HER2-positive breast cancer patients, nearing enrollment completion with results due mid-2021. Mytesi uniquely treats noninfectious diarrhea in HIV/AIDS patients and aims to address significant healthcare costs associated with chronic diarrhea.